EGFR and non-small cell lung carcinoma: Importantly, increased activity of immune responses induced by ICIs can increase the risk of ILD in patients with NSCLC carrying epidermal growth factor receptor (EGFR) mutations, not only when EGFR tyrosine kinase inhibitors, particularly osimertinib, were administered in combination with PD-1/PD-L1 inhibitors [9–11], but also when they were administered sequentially [9, 12].